| Literature DB >> 28533061 |
Motonori Mizutani1, Akiyoshi Takami2, Masahiko Hara3, Shohei Mizuno1, Masamitsu Yanada4, Takaaki Chou5, Hitoji Uchiyama6, Kazuteru Ohashi7, Toshihiro Miyamoto8, Yukiyasu Ozawa9, Osamu Imataki10, Naoki Kobayashi11, Naoyuki Uchida12, Heiwa Kanamori13, Tomohiko Kamimura14, Tetsuya Eto15, Makoto Onizuka16, Junji Tanaka17, Yoshiko Atsuta18, Shingo Yano19.
Abstract
Allogeneic stem cell transplantation (SCT) from an HLA-matched sibling donor (MSD) is a postremission treatment that offers a potential cure for adults with cytogenetically normal (CN) acute myelogenous leukemia (AML) in first complete remission (CR1). The best alternative in the absence of an MSD remains unclear, however. The aim of this study was to retrospectively compare the outcomes of autologous peripheral blood stem cell transplantation (auto-PBSCT; n = 177) and allogeneic bone marrow transplantation (BMT) from an HLA-matched unrelated donor (MUD; n = 173) in adult patients with CN-AML/CR1. Both the multivariate analysis (hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.71 to 1.97; P = .53) and propensity score models (HR, 1.40; 95% CI, 0.80 to 2.43; P = .24) indicated that the leukemia-free survival (LFS) rate of auto-PBSCT was not significantly different from that of MUD-BMT. These results suggest that in the absence of an available MSD, auto-PBSCT remains a viable alternative as postremission therapy in patients with CN-AML/CR1.Entities:
Keywords: Autologous peripheral blood stem cell transplantation; Leukemia-free survival; Matched unrelated donor bone marrow transplantation
Mesh：
Substances：
Year: 2017 PMID： 28533061 DOI： 10.1016/j.bbmt.2017.05.008
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN： 1083-8791 Impact factor: 5.742